gub014295
Peptideexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 29, 2023 (NCT06144684)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Islet amyloid polypeptideSupplementation
IAPP supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07291232 | Phase 1 | Nov 19, 2025 | AbbVie |
| NCT06144684 | Phase 1 | Nov 29, 2023 | Gubra ApS, Quotient |
Showing 2 of 2 trials
Page 1 / 1